Glycopyrronium Bromide Glenmark Pharmaceuticals Europe (Glycopyrronium Bromide)

Glycopyrronium bromide is primarily employed as a bronchodilator in the management of respiratory conditions.

• Maintenance therapy for chronic obstructive pulmonary disease (COPD) when anticholinergic treatment is indicated.
• Adjunctive treatment to improve lung function in patients with asthma who have a component of bronchoconstriction.
• Use in patients who require long‑acting muscarinic antagonist (LAMA) therapy to reduce exacerbations.
• May be considered for off‑label use in certain cases of hyperhidrosis under specialist guidance.
• Integration with inhaled corticosteroids may provide synergistic bronchodilatory effects in selected patient populations.
• Evaluation of lung function and symptom scores guides therapy adjustments when using glycopyrronium bromide.

The safety profile of glycopyrronium bromide includes both frequently observed and less common adverse events.

Common

• Dry mouth (xerostomia), which may affect swallowing and oral comfort.
• Constipation or reduced gastrointestinal motility, potentially leading to abdominal discomfort.
• Urinary retention, particularly in men with benign prostatic hyperplasia, requiring monitoring.
• Headache or mild dizziness, generally transient and self‑limiting.
• Dry eyes or blurred vision, which may affect reading or driving.

Serious

• Acute angle‑closure glaucoma precipitated by the anticholinergic effect, presenting with eye pain and visual disturbance.
• Severe tachycardia or cardiac arrhythmias that may necessitate medical evaluation.
• Allergic reactions such as rash, pruritus, or anaphylaxis, requiring immediate discontinuation and treatment.

When prescribing glycopyrronium bromide, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess renal and hepatic function, as impaired clearance may increase systemic exposure.
• Review patient history for glaucoma, especially narrow‑angle type, due to anticholinergic risk.
• Evaluate for urinary retention or prostate enlargement before initiating therapy.
• Use caution in patients with cardiovascular disease, including arrhythmias or tachycardia.
• Monitor for signs of severe dry mouth that could affect oral health or nutrition.
• Consider potential interactions with other anticholinergic agents that may amplify side effects.

Glycopyrronium bromide may interact with other medications, influencing its efficacy or safety profile.

Avoid

• Concomitant use with other potent anticholinergic drugs (e.g., atropine, scopolamine) that can exacerbate anticholinergic toxicity.
• Co‑administration with drugs that prolong QT interval, as additive cardiac risk may occur.

Use with caution

• Beta‑agonist bronchodilators, as combined bronchodilation may increase risk of tachycardia.
• Antihistamines with anticholinergic properties, which can intensify dry mouth and urinary retention.
• Diuretics, particularly thiazides, that may worsen electrolyte imbalance when combined with anticholinergic effects.
• Oral anticoagulants, where careful monitoring is advised due to potential changes in plasma protein binding.